

Novavax Investor Relations

GAITHERSBURG, Md., April 4, 2023 [/PRNewswire/](#) -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its [COVID-Influenza Combination vaccine candidate](#) (CIC) at both the [World Vaccine Congress 2023](#) (WVC) in Washington, DC, April 3 to 6, 2023, and the [33rd European Congress of Clinical Microbiology & Infectious Diseases](#) (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.

At WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax will also host an *Insights and Tools to Counter Vaccine Hesitancy* roundtable on April 4, and participate in a panel discussion on *The Future of Safety for New Vaccines* on April 5. In addition, Novavax has been named a finalist for the [2023 World Vaccine Congress Vaccine Industry Excellence Awards](#) (ViE) in the *Best New Vaccine Technology/Platform Award* and *Best COVID Vaccine Award* categories. Winners will be announced in-person at the ViE Awards ceremony during WVC on April 4.

At ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine.

Novavax presentations during WVC:

Author	Presentation title	Details
Dunkle, L	Novavax COVID-19 Vaccine: Latest Booster Data and Clinical Updates	Oral Presentation April 5, 2023 10:10am (EDT)
Shinde, V	Update on Novavax Influenza and COVID-Influenza Combination Vaccine	Oral Presentation April 5, 2023 3:25pm (EDT)
Fix, J	Safety surveillance for COVID-19 vaccines: challenges in the pandemic and endemic settings	Oral Presentation April 5, 2023 12:10pm (EDT)

Novavax presentations during ECCMID:

Author	Presentation title	Details
Shinde, V	Immunogenicity of a novel COVID-Influenza Combination (CIC) vaccine assessed with response surface modelling (RSM)	Oral Presentation Abstract #02042 April 16, 2023 8:30am (CEST)
Toback, S	Interim analysis of an observer-blinded, randomized phase 3 study to evaluate the safety and immunogenicity of a single booster of the NVX-CoV2373 vaccine in adults previously vaccinated with the BBIBP-CorV vaccine	Poster Presentation Poster #P2698 April 17, 2023 12:00pm (CEST)
Marchese, A	Reported pregnancy outcomes across NVX-CoV2373 COVID-19 vaccine primary series and booster dose clinical studies	Poster Presentation Poster #P2521 April 17, 2023 12:00pm (CEST)
Marchese, A	Healthcare provider perceptions of current and future uptake of COVID-19 vaccines in Europe and North America	Poster Presentation Poster #P2755 April 17, 2023 12:00pm (CEST)
Bennett, C	LATE-BREAKER: Immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M adjuvant (NVX-CoV2373) in well-controlled vs less well-controlled people living with HIV	Poster Presentation Poster #LB039 April 18, 2023 12:00pm (CEST)

About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit [novavax.com](https://www.novavax.com) and [LinkedIn](#) for more information.

The World Vaccine Congress

The World Vaccine Congress is a series of conferences and exhibitions that have grown over 23 years to become the largest vaccine meetings of their kind across the globe. The event format allows for whole-sector topics with hundreds of speakers and covers the complete vaccine value chain, enabling thousands of attendees from science, government, and manufacturers to come together to create ground-breaking progress. More information can be found at <https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm>.

CONTACTS

Investors

Erika Schultz
240-268-2022
ir@novavax.com

Media

Ali Chartan
240-720-7804
media@novavax.com

SOURCE Novavax, Inc.

<https://ir.novavax.com/2023-04-04-Novavax-Grows-Presence-at-World-Vaccine-Congress-2023-and-33rd-European-Congress-of-Clinical-Microbiology-Infectious-Diseases>